Drugs / AD-2141
last change Mar 2022 re-read 2 minutes ago

AD-2141

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05062876 Comparator Nov 2021 → Mar 2022 gastroesophageal reflux disease Addpharma Inc. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AD-2141 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05062876